Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:CLSNNASDAQ:JAGXNASDAQ:SAVANASDAQ:TLGT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.19-1.7%$1.82$1.08▼$5.50$9.59M0.9612,289 shs7,532 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsJAGXJaguar Health$0.17$0.09$0.05▼$1.22$46.93M1.3551.07 million shs33.93 million shsSAVACassava Sciences$20.74+0.9%$21.50$12.32▼$32.10$897.01M-0.45764,323 shs476,380 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+3.39%+5.17%-32.60%-54.14%-65.34%CLSNImunon0.00%0.00%0.00%0.00%0.00%JAGXJaguar Health-6.61%-5.78%+133.66%+63.58%-69.84%SAVACassava Sciences+0.24%-2.28%+3.74%-17.67%+26.02%TLGTTeligent0.00%0.00%0.00%0.00%0.00%The "Smart Money" Is Ready for May 1st Are You? (Ad)Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.4824 of 5 stars3.51.00.04.71.70.80.6TLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/ASAVACassava Sciences3.00Buy$124.00497.88% UpsideTLGTTeligentN/AN/AN/AN/ACurrent Analyst RatingsLatest CLSN, AKTX, TLGT, JAGX, and SAVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00JAGXJaguar Health$9.76M4.81N/AN/A$0.07 per share2.43SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ATLGTTeligentN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AJAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)SAVACassava Sciences-$97.22M-$2.32N/A12.42N/AN/A-57.53%-52.58%5/6/2024 (Estimated)TLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest CLSN, AKTX, TLGT, JAGX, and SAVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.950.95CLSNImunon0.136.526.52JAGXJaguar Health6.332.001.34SAVACassava SciencesN/A9.139.13TLGTTeligentN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%CLSNImunon12.97%JAGXJaguar Health12.04%SAVACassava Sciences38.05%TLGTTeligentN/AInsider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%CLSNImunon4.66%JAGXJaguar Health0.02%SAVACassava Sciences12.20%TLGTTeligent0.17%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics157.92 million3.03 millionNot OptionableCLSNImunon277.10 million6.77 millionOptionableJAGXJaguar Health49276.22 million276.16 millionNo DataSAVACassava Sciences2943.25 million37.97 millionOptionableTLGTTeligent2,357N/AN/AOptionableCLSN, AKTX, TLGT, JAGX, and SAVA HeadlinesSourceHeadlineTopical pain reliever recalled for problem that can cause ‘severe morbidity, even death’charlotteobserver.com - June 7 at 10:18 AMβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzznews.google.com - May 13 at 1:32 AMLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan Newsnews.google.com - May 13 at 1:32 AMGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Todaynews.google.com - May 11 at 4:41 AMGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examinernews.google.com - May 8 at 10:54 AMDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journalnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examinernews.google.com - May 5 at 9:12 AMEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journalnews.google.com - May 3 at 7:08 AMErythromycin Market with Focus on Growth Analysis, Production ... - Digital Journalnews.google.com - May 2 at 8:42 AMFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journalnews.google.com - April 29 at 8:17 AMTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRnews.google.com - April 28 at 10:17 PMDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRnews.google.com - April 26 at 1:32 PMTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRnews.google.com - April 26 at 8:32 AMTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan Newsnews.google.com - April 24 at 4:23 PMIDT Corp. Cl Bwsj.com - April 23 at 2:59 AMMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journalnews.google.com - April 17 at 2:17 PMHikma Names Injectables Chief Mishlawi As CEO - Generics Bulletinnews.google.com - April 12 at 1:13 PMMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journalnews.google.com - April 10 at 1:16 PMEverstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin Globenews.google.com - April 6 at 1:58 PMLidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital Journalnews.google.com - March 29 at 7:08 AMMobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital Journalnews.google.com - March 29 at 2:07 AMGonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPRnews.google.com - March 28 at 10:26 AMBankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD Supranews.google.com - March 25 at 8:59 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.TeligentNASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.